Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Among authors: bertagnolio s. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
Transmitted HIV drug resistance among drug-naive subjects recently infected with HIV in Mexico City: a World Health Organization survey to classify resistance and to field test two alternative patient enrollment methods.
Bertagnolio S, Rodriguez-Diaz RA, Fuentes-Romero LL, Bennett DE, Viveros-Rogel M, Hart S, Pilon R, Sandstrom P, Soto-Ramirez LE. Bertagnolio S, et al. Clin Infect Dis. 2012 May;54 Suppl 4:S328-33. doi: 10.1093/cid/cir938. Clin Infect Dis. 2012. PMID: 22544198
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.
Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. Gupta RK, et al. Among authors: bertagnolio s. Lancet. 2012 Oct 6;380(9849):1250-8. doi: 10.1016/S0140-6736(12)61038-1. Epub 2012 Jul 23. Lancet. 2012. PMID: 22828485 Free PMC article.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.
Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, Jordan MR, Hallett TB, Boucher CA, de Wit TF, van de Vijver DA. Nichols BE, et al. Among authors: bertagnolio s. J Int AIDS Soc. 2014 Dec 5;17(1):19164. doi: 10.7448/IAS.17.1.19164. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25491351 Free PMC article.
Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N, Rinke de Wit TF, Bertagnolio S. Boender TS, et al. Among authors: bertagnolio s. Clin Infect Dis. 2015 Nov 1;61(9):1453-61. doi: 10.1093/cid/civ556. Epub 2015 Jul 8. Clin Infect Dis. 2015. PMID: 26157050 Free PMC article. Review.
119 results